復銳醫療科技(01696.HK)年度收益3.49億美元 同比減少2.8%
格隆匯3月19日丨復銳醫療科技(01696.HK)發佈公告,截至2024年12月31日止年度收益爲349.1百萬美元,較去年收益減少2.8%。毛利率由2023年同期的61.1%增長至報告期的62.1%。年內溢利爲28.8百萬美元,較去年減少12.6%。董事會議決宣佈派發末期股息每股0.126港元(含稅)。
截至2024年12月31日止年度直銷收益佔總收益的87%,2023年同期則爲78%。截至2024年12月31日止年度,亞太、歐洲、中東及非洲的收益分別爲116.2百萬美元、50.5百萬美元及34.6百萬美元,較去年分別增加6.0%、0.7%及27.1%。在報告期內,受嚴峻高息環境持續衝擊行業的影響,北美地區營收同比減少12.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.